Jafron Biomedical (300529.SZ): As of now, the company's products have been widely used in more than 2,000 hospitals overseas.

Gelonghui Finance · Sep 13 04:03

Jafron Biomedical (300529.SZ) held a performance briefing on September 12, 2024, and in response to the question of "How is the internationalization of the company's products?", the company stated that up to now, its products have been widely used in more than 2,000 overseas hospitals, achieving product access in over 90 countries. This year, the company's HA series blood perfusors, BS series bilirubin adsorbers, KHA series blood perfusors, and CA series cytokine adsorption columns have obtained CE certification under the new EU Medical Device Regulation (MDR), which will actively promote the promotion and sales of the company's products in EU countries and other EU MDR recognized countries.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

健帆生物(300529.SZ)：截至目前，公司产品已在海外2000余家医院广泛应用

Jafron Biomedical (300529.SZ): As of now, the company's products have been widely used in more than 2,000 hospitals overseas.

Risk Disclaimer

Statement